Charlton Strange, MD
Critical Care Medicine · Charleston, SCNPI 1427155217
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $131,483 of the $204,587 with a category attached, or 64.3%. 18 manufacturers reported payments, led by CSL Behring at 29.4% of the total. Among critical care medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $1043.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$60K
- AstraZeneca$44K
- GSK$27K
- Sanofi$19K
- F. Hoffmann-la Roche AG$17K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- plus $27K from 12 others
Across 308 payments — averaging $3766.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$413K
- Grifols Therapeutics LLC$279K
- Vertex$192K
- Shire North American Group Inc$111K
- Biomarin Pharmaceutical Inc.$94K
- Grifols Biologicals LLC$60K
- plus $12K from 2 others
What the payments were for
- Consulting fees$131,48364%
- Speaking & faculty fees$30,04415%
- Travel & lodging$37,85819%
- Food & beverage$5,1303%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 30 | $60,154 |
| AstraZeneca | 69 | $43,667 |
| GSK | 17 | $26,617 |
| Sanofi | 6 | $18,628 |
| F. Hoffmann-la Roche AG | 7 | $17,459 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $11,367 |
| Vertex | 11 | $7,779 |
| Grifols USA, LLC | 8 | $6,827 |
| Uptake Medical Technology Inc | 3 | $5,550 |
| Genentech, Inc. | 2 | $2,090 |
| Vifor Pharma, Inc. | 1 | $1,460 |
| Astrazeneca AB | 3 | $1,070 |
| Eli Lilly | 2 | $1,000 |
| Pulmonx Corporation | 4 | $380 |
| Biomarin Pharmaceutical Inc. | 1 | $169 |
| United Therapeutics Corporation | 1 | $145 |
| Boehringer Ingelheim | 2 | $141 |
| Grifols Shared Services North America, Inc. | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zemaira$46,018
- GLASSIA$8,982
- FASENRA$7,244
- Archimedes System$4,200
- AIRSUPRA$3,718
- Prolastin-C Liquid$3,387
- BREZTRI$2,920
- TRELEGY ELLIPTA$2,275
- XOLAIR$2,090
- BREZTRI AEROSPHERE$1,167
- Pulmonx Endobronchial Valve EBV$209
- REMODULIN$145
- CHARTIS CATHETER$135
- ZEPHYR DELIVERY CATHETER$135
- ZEPHYR ENDOBRONCHIAL VALVE$135
- PULMONX CHARTIS TABLET CONSOLE$135
How this compares
$204,587 in reported general payments places this provider in the 95th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZemairaAlpha-1-Proteinase Inhibitor | 37 | $456,423 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 17 | $340,333 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 21 | $192,864 |
| Ambrisentan | 11 | $52,875 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $26,236 |
| Spiriva RespimatTiotropium Bromide | 21 | $19,089 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $11,152 |
| Spiriva HandihalerTiotropium Bromide | 15 | $8,431 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,931 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,204 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,922 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,598 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $1,231 |
| Prednisone | 51 | $327 |
| Azithromycin | 12 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringZemaira | $60,154 | $456,42337 claims |
| Grifols USA, LLCProlastin C | $6,827 | $192,86421 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $141 | $38,17251 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $26,617 | $32,44136 claims |
| AstraZenecaSymbicort | $43,667 | $4,92213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Charleston
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Nicholas FoxCharleston$88K
- Christopher GilbertCharleston$44K
- Gregory SquiresCharleston$14K
- John MitchellCharleston$10K
- Luca PaolettiCharleston$5K
- Jennings NestorCharleston$5K
- Tatsiana BeikoCharleston$4K
- Stephen SexauerCharleston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.